News & Updates

Treatment with belzutifan improves progression-free survival (PFS) and objective response rate (ORR) in East Asian patients with advanced clear-cell renal cell carcinoma (RCC) compared with everolimus, according to the updated subgroup data of the phase III LITESPARK-005 trial presented at ESMO Asia 2024.

New drug applications approved by US FDA as of 16-31 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Noninvasive diagnosis of metabolic dysfunction–associated steatohepatitis (MASH) may become a possibility with a robust blood-based biomarker panel developed by researchers from the Chinese University of Hong Kong (CUHK) and their collaborators in mainland China and the US, which demonstrated high diagnostic accuracy in Asian and American validation cohorts.

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Among patients with primary biliary cholangitis (PBC), treatment with elafibranor improved predicted transplant-free survival rates based on improvements in GLOBE and UK-PBC scores, according to the phase III ELATIVE trial presented at The Liver Meeting 2024.

Treatment with odevixibat led to rapid and sustained improvements in pruritus and serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), according to the final data of the phase III ASSERT-extension (ASSERT-EXT) study presented at The Liver Meeting 2024.

Among consumers of different types of alcohol, those who consume beer only have the lowest dietary quality compared with those confined to wine or liquor intake or those who consume multiple types of alcohol, according to data presented at TLM 2024.